- Home
- LBTYB vs LGND Comparison
LBTYB vs LGND Comparison
Compare LBTYB & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYB | LGND |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | LBTYB | LGND |
|---|---|---|
| Price | $10.80 | $200.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $243.50 |
| AVG Volume (30 Days) | 1.9K | ★ 223.7K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.76 |
| EPS | N/A | ★ 2.49 |
| Revenue | ★ $4,770,600,000.00 | $251,233,000.00 |
| Revenue This Year | $15.50 | $47.71 |
| Revenue Next Year | $1.62 | $9.77 |
| P/E Ratio | ★ N/A | $80.77 |
| Revenue Growth | ★ 170.50 | 64.83 |
| 52 Week Low | $9.15 | $93.58 |
| 52 Week High | $13.04 | $212.49 |
Technical Indicators
Market Signals| Indicator | LBTYB | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 53.29 |
| Support Level | $10.20 | $188.13 |
| Resistance Level | $11.00 | $207.06 |
| Average True Range (ATR) | 0.22 | 9.14 |
| MACD | -0.03 | 0.38 |
| Stochastic Oscillator | 37.15 | 69.37 |
Price Performance
Historical ComparisonAbout LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.